Odisha High Court Seeks Government Action on Advanced Blood Testing

Odisha High Court Seeks Government Action on Advanced Blood Testing

Introduction to Enhanced Blood Screening

The Orissa High Court recently requested a response from the state government regarding a Public Interest Litigation (PIL). This PIL advocates for implementing advanced Individual Donor Nucleic Acid Testing (ID-NAT) across all government-run and affiliated blood banks in Odisha. The petitioner, Dr. Amarendra Mohapatra, a retired scientist, argues that the current NAT-PCR technology is outdated and less effective for detecting crucial infections like HIV, HBV, and HCV. Notably, this move aims to significantly enhance blood safety protocols statewide. [4]

Understanding Individual Donor NAT (ID-NAT)

Individual Donor Nucleic Acid Testing (ID-NAT) represents a more sensitive and direct method for screening donated blood. It targets the genetic material of pathogens (RNA or DNA) rather than relying on the body’s immune response to produce antibodies or antigens. Consequently, ID-NAT significantly shortens the ‘window period’—the time between initial infection and detectable markers. Unlike minipool NAT (MP-NAT), which tests pooled samples, ID-NAT screens each donation individually. This ensures a higher sensitivity, as low viral loads, potentially missed in diluted pooled samples, become detectable. [1, 3, 7]

Advantages of ID-NAT for Enhanced Blood Safety

Implementing ID-NAT offers substantial benefits in reducing transfusion-transmitted infections (TTIs). This advanced technology allows for earlier detection of viruses such as HIV, Hepatitis B (HBV), and Hepatitis C (HCV), often before serological tests can identify them. For instance, ID-NAT can detect HIV-1 within 4.7 days, HCV within 2.2 days, and HBV within 15 days, significantly reducing the window period compared to traditional serological methods. [2, 9] Therefore, this method vastly improves the efficacy of blood screening, protecting recipients from potentially infectious units. Major institutions like AIIMS Delhi, AIIMS Rishikesh, AIIMS Bhubaneswar, and ILBS Delhi have already adopted ID-NAT, proving its effectiveness and reliability. [4] This focus on advanced diagnostic techniques is crucial for professionals aiming to improve patient care and safety, aligning with the principles taught in a Certification Course In Hematology.

ID-NAT Implementation and Challenges in India

Despite the clear advantages, the universal adoption of NAT, including Individual Donor NAT, faces challenges across India. While private hospitals in urban areas have increasingly implemented NAT testing, many trust and government blood centers still rely on older methods like ELISA or rapid tests. [1] Historically, only a small percentage of India’s blood banks have performed NAT testing. [5] Arguments against universal implementation often cite the high cost per unit of blood tested, especially considering the marginal reduction in the window period for some infections compared to the expense. [1, 2] Nevertheless, studies consistently show a significant ‘NAT yield,’ identifying infectious units that serological tests miss, particularly for HBV. [5, 12, 14] Consequently, this highlights the pressing need for broader adoption of ID-NAT to further safeguard the national blood supply. [6]

Frequently Asked Questions

Q1: What is the main difference between ID-NAT and older blood testing technologies?

ID-NAT (Individual Donor Nucleic Acid Testing) directly detects the genetic material (DNA/RNA) of viruses like HIV, HBV, and HCV in individual blood donations. Older technologies, like NAT-PCR mentioned in the article, or serological tests (ELISA), primarily look for antibodies or antigens produced by the body, which appear later in an infection. ID-NAT significantly shortens the ‘window period’ for detection, thus identifying infections much earlier. [3, 9]

Q2: Why is the implementation of ID-NAT considered crucial for blood safety in India?

ID-NAT is vital for enhancing blood safety because it can detect transfusion-transmitted infections (TTIs) during the crucial window period when traditional tests might yield false negatives. India faces high prevalence rates of infections like HBV, HCV, and HIV among its population. Therefore, adopting a highly sensitive method like ID-NAT can prevent these undetected infections from being transmitted through blood transfusions, thereby improving overall public health outcomes. [2, 9, 13] Understanding these critical aspects of infectious diseases is fundamental for medical professionals, as explored in the Postgraduate Diploma In Infectious Disease.

Q3: Which institutions in India have already adopted ID-NAT?

Several prominent medical institutions in India have already embraced ID-NAT technology. These include AIIMS Delhi, AIIMS Rishikesh, AIIMS Bhubaneswar, and ILBS Delhi. Their adoption underscores the recognized benefits of ID-NAT in providing more accurate and timely detection of blood-borne infections. [4]

References

1. Orissa high court seeks government response on advanced blood testing technologyin Odisha – ETHealthworld
2. Nucleic acid testing: Is it the only answer for safe Blood in India? – PMC – PubMed Central
3. AN EXPERIENCE WITH ID‐NAT AND IT’S ROLE TO REFINE BLOOD SAFETY AGAINST THE TRANSFUSION‐TRANSMITTED INFECTIONS
4. ID-NAT Tested Blood for Better Blood Transfusion – IndiaMedToday
5. Orissa high court seeks government response on advanced blood testing technology in Odisha | Bhubaneswar News – The Times of India
6. Nucleic acid amplification testing in Indian blood banks: A review with perspectives | Request PDF – ResearchGate
7. Nucleic acid testing-benefits and constraints – PMC
8. (PDF) 2018- the role of ID-NAT in Enhancing blood safety at the ENCI blood Bank
9. Individual donor-nucleic acid testing for human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safety – PMC
10. The importance of individual donor nucleic acid amplification testing (ID-NAT) in further ensuring the safety and – Hemogenomics
11. Impact of nucleic acid testing in double screening of blood donations in Northern India: A single-center experience – Journal of Laboratory Physicians
12. Initial trends of individual donation nucleic acid testing in voluntary & replacement donors from a tertiary care centre in north India
13. Individual Donor Nucleic Acid Testing for HIV, HBV and HCV among Blood Donors in a Tertiary Care Hospital – International Journal of Current Microbiology and Applied Sciences (IJCMAS)
14. Experience of Individual Donor Nucleic Acid Testing on Screening of Blood Donors for Human Immunodeficiency Virus, Hepatitis C Virus, and Hepatitis B Virus at an Apex Blood Bank of Northern India – ResearchGate

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.